Vidofludimus (hemicalcium) [1354012-90-0]

MedChem Express

Vidofludimus (hemicalcium) [1354012-90-0]

10

1354012-90-0

Research Use Only

C20H18FNO4.1/2Ca

375.40

Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR[1][2][3].

O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O.[Ca].[1/2]

12131703